Disclosure Of Entity's Operating Segments [Text Block]

ABIONYX Pharma - Filing #2821124

Concept 2020-01-01 to
2020-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
As at
2019-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
0 EUR
0 EUR
Interest expense
0 EUR
0 EUR
Tax expense (income)
0 EUR
38,000 EUR
Profit (loss)
1 886 EUR
1 886 EUR
1 849 EUR
1 849 EUR
Assets
10 288 EUR
10 249 EUR
Cash flows from (used in) operating activities
599,000 EUR
3 950 EUR
Cash flows from (used in) investing activities
125,000 EUR
0 EUR
Cash flows from (used in) financing activities
1 547 EUR
823,000 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.